Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial o

Moderna Shares Double on Success of mRNA Cancer Vaccine  WSJ

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial.  The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically removed. In early results

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner

Optimism about a potential breakthrough in personalised cancer treatment has sent shares in Moderna soaring by nearly 100%.

Women with breast cancer who were left languishing in PBS drug uncertainty have been offered a lifeline.

A JAMA Surgery study of over two million patients found that cancer treatment delays grew by more than 10 days across six disease types.

Astra said its Volrustomig treatment, when combined with chemotherapy, was unlikely to help lung cancer patients live longer than rival offerings.